EU/3/15/1541: Orphan designation for the treatment of marginal zone lymphoma

Ibrutinib

Table of contents

Overview

Please note that this product was withdrawn from the Union Register of orphan medicinal products in October 2021 on request of the sponsor.

On 10 August 2015, orphan designation (EU/3/15/1541) was granted by the European Commission to Janssen-Cilag International N.V., Belgium, for ibrutinib for the treatment of marginal zone lymphoma.

Key facts

Active substance
Ibrutinib
Intended use
Treatment of marginal zone lymphoma
Orphan designation status
Withdrawn
EU designation number
EU/3/15/1541
Date of designation
10/08/2015
Sponsor

Janssen-Cilag International N.V.
Turnhoutseweg, 30
2340 Beerse
Belgium
Tel. +32 146 031 89
Fax +32 146 055 33
E-mail: http://www.janssen-emea.com/contactus

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating